Trial Profile
Kevzara (Sarilumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Sanofi
- 01 Dec 2022 Planned End Date changed from 1 Aug 2027 to 8 Feb 2024.
- 01 Dec 2022 Planned primary completion date changed from 1 Aug 2027 to 8 Feb 2024.
- 25 Oct 2022 Status changed from recruiting to active, no longer recruiting.